Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2008

01-08-2008 | Article

Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis

Authors: E. Force, F. Taberner, C. Cabellos, S. Ribes, A. Domenech, F. Tubau, P. F. Viladrich, F. Gudiol

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2008

Login to get access

Abstract

Meropenem is a carbapenem antibiotic that is highly active against the pathogens causing meningitis. Results with meropenem in the experimental rabbit model of penumococcal meningitis have been controversial, and the possible role of renal dehydropeptidase I in meropenem efficacy has been suggested. The aim of this study was to determine the efficacy of meropenem in two meningitis models and the possible influence of the animal model over results. Two strains of Streptococcus pneumoniae with different susceptibility to beta-lactams have been used in a guinea pig model and the classical rabbit meningitis model. Meropenem was bactericidal at 6 h in the guinea pig model against both strains with a reduction of >4 log ufc/ml. In the rabbit model it was bactericidal at 6 h against the susceptible strain, but against the resistant 3/8 therapeutical failures were recorded at 6 h, being bactericidal at 24 h. In conclusion, meropenem has shown bactericidal activity in both experimental models. This work emphasises the importance of an adequate election of the animal model for the appropriate development of studies of antimicrobial efficacy. We believe that guinea pig should be considered the best choice among laboratory animal species when assessing meropenem efficacy.
Literature
1.
go back to reference Dagan R, Velghe L, Rodda JL, Klugman KP (1994) Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J Antimicrobial Chemother 34:175–179CrossRef Dagan R, Velghe L, Rodda JL, Klugman KP (1994) Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J Antimicrobial Chemother 34:175–179CrossRef
2.
go back to reference Schmutzhard E, Williams KJ, Vukmirovits G, Chemlik V, Pfausler B, Featherstone A (1995) A randomize comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group J Antimicrobial. Chemother 36(Suppl A):85–97 Schmutzhard E, Williams KJ, Vukmirovits G, Chemlik V, Pfausler B, Featherstone A (1995) A randomize comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group J Antimicrobial. Chemother 36(Suppl A):85–97
3.
go back to reference Klugman KP, Dagan R, Meropenem Study Group (1995) Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother 39:1140–1146PubMed Klugman KP, Dagan R, Meropenem Study Group (1995) Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother 39:1140–1146PubMed
4.
go back to reference Odio CM, Puig JR, Feris JM, Khan WN, Rodriguez WJ, McCracken GH, Bradley JD (1999) Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children Meropenem Study Group. Pediatr Infect Dis J 18:581–590PubMedCrossRef Odio CM, Puig JR, Feris JM, Khan WN, Rodriguez WJ, McCracken GH, Bradley JD (1999) Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children Meropenem Study Group. Pediatr Infect Dis J 18:581–590PubMedCrossRef
5.
go back to reference Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ (2004) Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39:1267–1284PubMedCrossRef Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ (2004) Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39:1267–1284PubMedCrossRef
6.
go back to reference Fitoussi F, Doit C, Benali K, Boacorsi S, Gelsin P, Bingen E (1998) Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin resistant Streptococcus pneumoniae isolates from children with meningitis. Antimicrob Agents Chemother 42:942–944PubMed Fitoussi F, Doit C, Benali K, Boacorsi S, Gelsin P, Bingen E (1998) Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin resistant Streptococcus pneumoniae isolates from children with meningitis. Antimicrob Agents Chemother 42:942–944PubMed
7.
go back to reference Norrby SR (2000) Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrobial Chemother 45:5–7CrossRef Norrby SR (2000) Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrobial Chemother 45:5–7CrossRef
8.
go back to reference Gerber CM, Cottagnoud M, Neftel KA, Täuber MG, Cottagnoud P (1999) Meropenem alone and in combination with vancomicin in experimental meningitis caused by a penicillin-resistant pneumoccocal strain. Eur J Clin Microbiol Infect Dis 18:886–870CrossRef Gerber CM, Cottagnoud M, Neftel KA, Täuber MG, Cottagnoud P (1999) Meropenem alone and in combination with vancomicin in experimental meningitis caused by a penicillin-resistant pneumoccocal strain. Eur J Clin Microbiol Infect Dis 18:886–870CrossRef
9.
go back to reference Friedland IR, Paris M, Ehrett S, Hickey S, Olsen K, McCracken JR (1993) Evaluation of antimicrobial regimens for treatment of experimental penicillin and cephalosporin resistant pneumococcal meningitis. Antimicrob Agents Chemother 37:1630–1636PubMed Friedland IR, Paris M, Ehrett S, Hickey S, Olsen K, McCracken JR (1993) Evaluation of antimicrobial regimens for treatment of experimental penicillin and cephalosporin resistant pneumococcal meningitis. Antimicrob Agents Chemother 37:1630–1636PubMed
10.
go back to reference Fukasawa M, Sumita Y, Harabe ET, Tanio T, Nouda H, Kohzuki et al (1992) Stability of meropenem and effect of 1β-methil substitution on its stability in the presence of renal dehydropeptidase I. J Antimicrobial Chemother 36:1577–1579 Fukasawa M, Sumita Y, Harabe ET, Tanio T, Nouda H, Kohzuki et al (1992) Stability of meropenem and effect of 1β-methil substitution on its stability in the presence of renal dehydropeptidase I. J Antimicrobial Chemother 36:1577–1579
11.
go back to reference Nairn K, Shepherd GL, Edwards JR (1995) Efficacy of meropenem in experimental meningitis. J Antimicrobial Chemother 36(Suppl A):73–84 Nairn K, Shepherd GL, Edwards JR (1995) Efficacy of meropenem in experimental meningitis. J Antimicrobial Chemother 36(Suppl A):73–84
12.
go back to reference National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically-(2000) 5th edn: Approved Standard M7-A5 NCCLS, Wayne, PA National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically-(2000) 5th edn: Approved Standard M7-A5 NCCLS, Wayne, PA
13.
go back to reference Maiques JM, Domenech A, Cabellos C, Fernández A, Ribes S, Tubau F et al (2007) Evaluation of antimicrobial regimens in a guinea-pig model of meningitis caused by Pseudomonas aeruginosa. Microb Infect 9:435–441CrossRef Maiques JM, Domenech A, Cabellos C, Fernández A, Ribes S, Tubau F et al (2007) Evaluation of antimicrobial regimens in a guinea-pig model of meningitis caused by Pseudomonas aeruginosa. Microb Infect 9:435–441CrossRef
14.
go back to reference Dacey RG, Sande MA (1974) Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother 6:437–41PubMed Dacey RG, Sande MA (1974) Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother 6:437–41PubMed
15.
go back to reference Chapin-Robertson K, Edberg SC (1991) Measurements of antibiotics in human body fluids: techniques and significance. In: Lorian V (ed) Antibiotics in laboratory medicine. Williams and Wilkins, New York, pp 295–366 Chapin-Robertson K, Edberg SC (1991) Measurements of antibiotics in human body fluids: techniques and significance. In: Lorian V (ed) Antibiotics in laboratory medicine. Williams and Wilkins, New York, pp 295–366
16.
go back to reference Cottagnoud P, Cottagnoud M, Acosta F, Flatz L, Kühn, Stucki A, Entenza J (2003) Meropenem prevents levofloxacin induced resistance in penicillin resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis. Eur J Clin Microbiol Infect Dis 22:656–662 Cottagnoud P, Cottagnoud M, Acosta F, Flatz L, Kühn, Stucki A, Entenza J (2003) Meropenem prevents levofloxacin induced resistance in penicillin resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis. Eur J Clin Microbiol Infect Dis 22:656–662
Metadata
Title
Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis
Authors
E. Force
F. Taberner
C. Cabellos
S. Ribes
A. Domenech
F. Tubau
P. F. Viladrich
F. Gudiol
Publication date
01-08-2008
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2008
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-008-0492-8

Other articles of this Issue 8/2008

European Journal of Clinical Microbiology & Infectious Diseases 8/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine